

MSTCVS Quality Collaborative
2024 VBR Quality Improvement Initiatives
Final Report

*Due to the Coordinating Center October 21, 2024*

|  |  |
| --- | --- |
| Hospital Name: |  |
| Submitted by: |  |
| Date: |  |

|  |
| --- |
| **2024 MSTCVS VBR Measure #1***\*Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted* |
| VBR Quality Initiative: | **Pathologic sampling of 3 mediastinal and 1 hilar lymph node station at the time of lung cancer resection** |
| Target Patient Population: | New primary lung cancer patients undergoing lobectomy, segmentectomy, pneumonectomy, or therapeutic wedge resection |
| Baseline Data: |  |
| 2024 Goal: | 82% |
| Results: | Q1 2024: | Q2 2024: | Q3 2024: | Jan-Sept 2024: |
| Was the progress of this QI reviewed by a multidisciplinary team?If yes, please list disciplines: |  |
| Please describe all interventions and strategies and when they were implemented: |  |
| Please describe any challenges or barriers that were encountered and how your team overcame them: |  |
| Additional information, comments, or observations: |  |

|  |
| --- |
| **2024 MSTCVS VBR Measure #2***\*Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted* |
| VBR Quality Initiative: | **Days from surgeon consult to date of surgery** |
| Target Patient Population: | Clinical stage ≤T1N0, never or past smokers, undergoing lobectomy, segmentectomy, pneumonectomy, and therapeutic wedge resection (excludes preoperative chemoradiation for same disease) |
| Baseline Data: |  |
| 2024 Goal: | 32 days  |
| Results: | Q1 2024: | Q2 2024: | Q3 2024: | Jan-Sept 2024: |
| Was the progress of this QI reviewed by a multidisciplinary team?If yes, please list disciplines: |  |
| Please describe all interventions and strategies and when they were implemented: |  |
| Please describe any challenges or barriers that were encountered and how your team overcame them: |  |
| Additional information, comments, or observations: |  |

|  |
| --- |
| **2024 MSTCVS VBR Measure #3***\*Reimbursement will not be awarded without evidence that a plan was implemented and/or if no reports are submitted* |
| VBR Quality Initiative: | **Percentage of cases with documentation summitted for postoperative referral to medical oncology for**  |
| Target Patient Population: | Lobectomy, segmentectomy, pneumonectomy and therapeutic wedge resection with stage IB-IIIA |
| Baseline Data: | N/A |
| 2024 Goal: | 80% |
| Results: | Q1 2024: | Q2 2024: | Q3 2024: | Jan-Sept 2024: |
| Was the progress of this QI reviewed by a multidisciplinary team?If yes, please list disciplines: |  |
| Please describe all interventions and strategies and when they were implemented: |  |
| Please describe any challenges or barriers that were encountered and how your team overcame them: |  |
| Additional information, comments, or observations: |  |